BACKGROUND: Conservative management of aggressive prostate cancer in the elderly without definitive therapy has been associated with a 10-year prostate cancer-specific mortality of approximately 50%. The authors examined the prevalence of definitive therapy in elderly patients with intermediate-risk or high-risk disease. METHODS: 411,343 patients who were diagnosed from 2004 through 2012 with intermediate-risk or high-risk prostate cancer were identified in the National Cancer Database. Multivariable logistic regression adjusting for sociodemographic characteristics and comorbidity was used to examine the association between age and receipt of definitive therapy, defined as radical prostatectomy or radiotherapy, and of primary androgen deprivation therapy (ADT) among patients who did not receive definitive therapy. RESULTS: In total, 87.1% of high-risk patients and 91.9% of intermediate-risk patients received definitive therapy. When stratified by age, 93.7%, 92.1%, 90.8%, 87.6%, 80.9%, and 55.2% of high-risk patients and 96.1%, 94.7%, 93.4%, 89.7%, 82.7%, and 62.8% of intermediate-risk patients ages <60, 60 to 64, 65 to 69, 70 to 74, 75 to 79, and ≥80 years received definitive therapy, respectively. For both high-risk and intermediate-risk patients, increasing age was significantly associated with a decreased likelihood of receiving definitive therapy overall (both P < .001) and a greater likelihood of receiving primary ADT among those who did not receive definitive therapy (both P < .001). CONCLUSIONS: Older age was significantly associated with a decreased likelihood of receiving definitive therapy and an increased likelihood of receiving primary ADT in this national cohort of patients with intermediate-risk or high-risk prostate cancer. Notably, approximately 40% to 45% of patients aged ≥80 years did not receive definitive therapy. These findings are alarming given the dismal outcomes of conservatively managed unfavorable-risk prostate cancer. Cancer 2017;123:4832-40.
BACKGROUND: Conservative management of aggressive prostate cancer in the elderly without definitive therapy has been associated with a 10-year prostate cancer-specific mortality of approximately 50%. The authors examined the prevalence of definitive therapy in elderly patients with intermediate-risk or high-risk disease. METHODS: 411,343 patients who were diagnosed from 2004 through 2012 with intermediate-risk or high-risk prostate cancer were identified in the National Cancer Database. Multivariable logistic regression adjusting for sociodemographic characteristics and comorbidity was used to examine the association between age and receipt of definitive therapy, defined as radical prostatectomy or radiotherapy, and of primary androgen deprivation therapy (ADT) among patients who did not receive definitive therapy. RESULTS: In total, 87.1% of high-risk patients and 91.9% of intermediate-risk patients received definitive therapy. When stratified by age, 93.7%, 92.1%, 90.8%, 87.6%, 80.9%, and 55.2% of high-risk patients and 96.1%, 94.7%, 93.4%, 89.7%, 82.7%, and 62.8% of intermediate-risk patients ages <60, 60 to 64, 65 to 69, 70 to 74, 75 to 79, and ≥80 years received definitive therapy, respectively. For both high-risk and intermediate-risk patients, increasing age was significantly associated with a decreased likelihood of receiving definitive therapy overall (both P < .001) and a greater likelihood of receiving primary ADT among those who did not receive definitive therapy (both P < .001). CONCLUSIONS: Older age was significantly associated with a decreased likelihood of receiving definitive therapy and an increased likelihood of receiving primary ADT in this national cohort of patients with intermediate-risk or high-risk prostate cancer. Notably, approximately 40% to 45% of patients aged ≥80 years did not receive definitive therapy. These findings are alarming given the dismal outcomes of conservatively managed unfavorable-risk prostate cancer. Cancer 2017;123:4832-40.
Authors: Ted A Skolarus; Megan Ev Caram; Christina H Chapman; David C Smith; Brent K Hollenbeck; Sarah Hawley; Alexander Tsodikov; Anne Sales; Daniela Wittmann; Alexander Zaslavsky Journal: Cancer Date: 2018-09-07 Impact factor: 6.860
Authors: Amy R MacKenzie; Andrea M Barsevick; Ronald Myers; Sarah E Hegarty; Scott W Keith; Sheel Patel; Evan Lapinsky; Joshua Schoppe; Ulysses Williams; Andrew E Chapman Journal: J Geriatr Oncol Date: 2019-03-06 Impact factor: 3.929
Authors: Ted A Skolarus; Jane Forman; Jordan B Sparks; Tabitha Metreger; Sarah T Hawley; Megan V Caram; Lesly Dossett; Alan Paniagua-Cruz; Danil V Makarov; John T Leppert; Jeremy B Shelton; Kristian D Stensland; Brent K Hollenbeck; Vahakn Shahinian; Anne E Sales; Daniela A Wittmann Journal: Implement Sci Commun Date: 2021-10-28
Authors: Ted A Skolarus; Sarah T Hawley; Daniela A Wittmann; Jane Forman; Tabitha Metreger; Jordan B Sparks; Kevin Zhu; Megan E V Caram; Brent K Hollenbeck; Danil V Makarov; John T Leppert; Jeremy B Shelton; Vahakn Shahinian; Sriram Srinivasaraghavan; Anne E Sales Journal: Implement Sci Date: 2018-11-29 Impact factor: 7.327